|
MEDIPOST Biomedical Research Institute has
made R&D efforts for over 10 years
for developing adult stem cell drugs
to meet unmet medical needs in areas
such as osteoarthritis, stroke, Alzheimer's
disease, bronchopulmonary dysplasia
(BPD) and improving efficacy of hematopoietic
stem cell transplantation (HSCT).
Human cord blood-derived Mesenchymal Stem Cells (hUCB-MSCs) are
a robust source for not only giving
rise to a new cell type in need but
also for secreting various trophic factors
which will signal the activation of
host's own stem cells for producing
required cell types.
Allogeneic hUCB-derived hematopoietic stem cells (hUCB-HSCs)
and hUCB-MSCs have been proven to be
safe for transplantation to unrelated
recipients for over two decades.
Based
on our scientific achievements together
with proven safety on allogeneic hUCB-MSC
transplantation, at MEDIPOST, we aspire
to lead the development and commercialization
of adult stem cell drugs to help benefit
patients suffering from incurable diseases.
|
